Conversely, the latter two monoclonal antibodies are used to treat recurrent or metastatic (R/M) HNSCC by blocking the interaction between PD-L1 and programmed cell death protein 1 (PD-1) receptor [167]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.